Page last updated: 2024-12-05

felbamate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Felbamate is an anticonvulsant medication used to treat partial seizures and generalized tonic-clonic seizures in adults and children. It is also used to treat Lennox-Gastaut syndrome, a rare and severe form of epilepsy. Felbamate is thought to work by blocking the activity of certain neurotransmitters in the brain, including glutamate, which is involved in the transmission of nerve impulses. It is synthesized by reacting 2-amino-2-methylpropanol with diethyl carbonate. Felbamate has been shown to be effective in treating seizures in patients who have not responded to other anticonvulsant medications. It is also effective in treating Lennox-Gastaut syndrome, a rare and severe form of epilepsy. It is a unique anticonvulsant because of its mechanism of action and its effectiveness in treating refractory epilepsy. It is studied for its potential to be used in combination with other anticonvulsants to improve seizure control.'

Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3331
CHEMBL ID1094
CHEBI ID4995
SCHEMBL ID34947
MeSH IDM0136828

Synonyms (144)

Synonym
BIDD:GT0463
nsc-759866
CHEMBL1094
MLS001077299
HMS3266L12
AB00382985-18
BRD-K99107520-001-01-9
1,3-propanediol, 2-phenyl-, dicarbamate
2-phenyl-1,3-propanediol dicarbamate
MLS000028465 ,
taloxa
felbamyl
EU-0100524
add-03055
w 554
felbamatum [latin]
w-554
felbamato [spanish]
carbamic acid, 2-phenyltrimethylene ester
felbatol
felbamate [usan:inn]
brn 3345236
einecs 247-001-4
2-phenylpropane-1,3-diyl dicarbamate
NCGC00023092-02
lopac-f-0778
NCGC00015429-01
tocris-0869
BPBIO1_001258
BIOMOL-NT_000203
LOPAC0_000524
C07501
felbamate
25451-15-4
carbamic acid 3-carbamoyloxy-2-phenyl-propyl ester
carbamic acid 2-phenyltrimethylene ester
DB00949
felbatol (tn)
D00536
felbamate (uspinn)
NCGC00023092-06
smr000058448
PRESTWICK0_000919
NCGC00015429-02
NCGC00023092-05
NCGC00023092-04
NCGC00015429-06
HMS2093P19
F 0778 ,
NCGC00015429-09
bdbm50088430
felbamatum
felbamato
CHEBI:4995 ,
(3-carbamoyloxy-2-phenylpropyl) carbamate
NCGC00015429-08
HMS3261J09
cas-25451-15-4
tox21_302368
dtxcid903041
NCGC00255275-01
dtxsid9023041 ,
(3-aminocarbonyloxy-2-phenyl-propyl) carbamate
carbamic acid (3-carbamoyloxy-2-phenylpropyl) ester
A817858
nsc759866
pharmakon1600-01505600
tox21_110145
CCG-204614
HMS2234H06
NCGC00015429-04
NCGC00015429-05
NCGC00015429-07
NCGC00015429-11
NCGC00015429-10
NCGC00015429-03
x72rbb02n8 ,
hsdb 7525
4-06-00-05993 (beilstein handbook reference)
nsc 759866
unii-x72rbb02n8
FT-0630517
LP00524
2-phenyl-1,3-propanediol 1,3-dicarbamate
felbamate [mi]
felbamate [hsdb]
felbamate [mart.]
felbamate [usp-rs]
felbamate [usp monograph]
felbamate [usan]
felbamate [vandf]
felbamate [inn]
felbamate [orange book]
felbamate [who-dd]
S1330
AKOS015895100
HMS3370I06
gtpl5473
3-(carbamoyloxy)-2-phenylpropyl carbamate
add 03055
HY-B0184
CS-2068
SCHEMBL34947
NCGC00015429-14
tox21_110145_1
KS-1171
tox21_500524
NCGC00261209-01
Q-100326
2-phenyl-1,3-propanedioldicarbamate
AB00382985_19
OPERA_ID_1738
mfcd00865296
(3-carbamoyloxy-1,1,3,3-tetradeuterio-2-phenylpropyl) carbamate
EX-A591
AC-8197
felbamate, united states pharmacopeia (usp) reference standard
HMS3657I11
SR-01000000089-2
SR-01000000089-4
SR-01000000089-7
sr-01000000089
SBI-0050507.P002
HMS3715D20
SW197633-2
Q421301
Z1521554005
HMS3675P21
BCP27941
HMS3411P21
BRD-K99107520-001-18-3
BRD-K99107520-001-09-2
EN300-119542
SDCCGSBI-0050507.P003
HMS3884E11
NCGC00015429-24
w-554;add-03055
2 phenyl 1,3 propanediol dicarbamate
felbamate (mart.)
felbamatum (latin)
felbamate (usp monograph)
n03ax10
felbamate (usp-rs)
ae2 - newer anti-epileptic drug mixtures 2

Research Excerpts

Overview

Felbamate (FBM) is an antiepileptic drug that has minimal toxicity in preclinical toxicological species but has a serious idiosyncratic drug toxicity (IDT) in humans. Felbamate is an effective medication for a wide range of epilepsy syndromes in children younger than 4 years.

ExcerptReferenceRelevance
"Felbamate (FBM) is an antiepileptic drug that has minimal toxicity in preclinical toxicological species but has a serious idiosyncratic drug toxicity (IDT) in humans. "( Assessment of metabolic activation of felbamate in chimeric mice with humanized liver in combination with in vitro metabolic assays.
Ishida, Y; Kotake, Y; Ohta, S; Sanoh, S; Sato, K; Tateno, C, 2022
)
2.44
"Felbamate is a second-generation antiepileptic drug that can be used as add-on therapy to standard antiepileptic drugs."( Felbamate add-on therapy for drug-resistant focal epilepsy.
Bresnahan, R; Dong, J; Geng, J; Martin-McGill, KJ; Ni, H; Shi, LL, 2022
)
2.89
"Felbamate is an anti-seizure drug with established pharmacokinetic and safety data for dogs, but little published evidence of efficacy for managing generalized seizures in this species."( Felbamate as an oral add-on therapy in six dogs with presumptive idiopathic epilepsy and generalized seizures resistant to drug therapy.
Dewey, CW; Rishniw, M; Sakovitch, K,
)
2.3
"Felbamate is a second-generation antiepileptic drug that can be used as add-on therapy to standard antiepileptic drugs."( Felbamate add-on therapy for drug-resistant focal epilepsy.
Bresnahan, R; Dong, J; Geng, J; Martin-McGill, KJ; Ni, H; Shi, LL, 2019
)
2.68
"Felbamate is an anticonvulsant used in the treatment of epilepsy. "( Felbamate produces antidepressant-like actions in the chronic unpredictable mild stress and chronic social defeat stress models of depression.
Chen, Q; Li, X; Li, Z; Liu, C; Wang, H; Yin, S; You, Z, 2019
)
3.4
"Felbamate is an effective medication for a wide range of epilepsy syndromes in children younger than 4 years. "( Efficacy and safety of felbamate in children under 4 years of age: a retrospective chart review.
Balestri, P; Berardi, R; Coppola, G; Cordelli, DM; Franzoni, E; Grosso, S; Verrotti, A, 2008
)
2.1
"Felbamate is a derivative of meprobamate used in second-line partial epilepsy and in the Lennox-Gastaut syndrome. "( [Therapeutic drug monitoring of felbamate].
Bentué-Ferrer, D; Tribut, O; Verdier, MC,
)
1.86
"Felbamate is an antiepileptic drug used to treat refractory seizures and has minor side effects when given in recommended doses."( Urolithiasis in patients on high dose felbamate.
Durkee, CT; Fryjoff, KM; Ghousheh, AI; Groth, TW; Mandel, NS; Roddy, JT; Wille, DF, 2013
)
1.38
"Felbamate (FBM) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) currents, but the exact molecular action remains unclear. "( Use-dependent inhibition of the N-methyl-D-aspartate currents by felbamate: a gating modifier with selective binding to the desensitized channels.
Chang, HR; Hsieh, CP; Kuo, CC; Lin, BJ, 2004
)
2
"Felbamate is an antiepileptic drug that is associated with minimal toxicity in preclinical species such as rat and dog but has an unacceptable incidence of serious idiosyncratic reactions in man. "( Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression.
Johnson, MD; Kao, LM; Kelley, MF; Leone, AM; Lord, PG; McMillian, MK; Nie, AY; Parker, JB; Parkinson, A; Usuki, E, 2007
)
2.14
"Felbamate (FBM) is a potent nonsedative anticonvulsant whose clinical effect is chiefly related to gating modification (and thus use-dependent inhibition) rather than pore block of N-methyl-D-aspartate (NMDA) channels at pH 7.4. "( Extracellular proton-modulated pore-blocking effect of the anticonvulsant felbamate on NMDA channels.
Chang, HR; Kuo, CC, 2007
)
2.01
"Felbamate is a new antiepileptic drug approved for partial and secondarily generalized seizures."( The effect of felbamate on valproic acid disposition.
Graves, NM; Leppik, IE; Perhach, JL; Remmel, RP; Shumaker, RC; Wagner, ML; Ward, DL, 1994
)
2.09
"Felbamate is a new anticonvulsant which has already been marketed in some countries outside Germany, i. "( [The pharmacologic and clinical profile of the new anticonvulsant felbamate--an overview].
Steinhoff, BJ, 1994
)
1.97
"Felbamate is a promising new antiepileptic drug whose mechanism of action is unknown. "( Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors.
Donevan, SD; Rho, JM; Rogawski, MA, 1994
)
2
"Felbamate (FBM) is a new antiepileptic drug (AED) that has been evaluated in partial seizures and in the Lennox-Gastaut syndrome (LGS). "( Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial.
Dodson, WE, 1993
)
3.17
"Felbamate (FBM) is a new antiepileptic drug (AED) that has been tested in open and controlled studies in patients with therapy-refractory partial-onset seizures. "( Felbamate in the treatment of refractory partial-onset seizures.
Jensen, PK, 1993
)
3.17
"Felbamate (FBM) is an effective and safe novel antiepileptic drug (AED) for add-on treatment in adults with refractory partial seizures as shown in three pivotal controlled trials. "( Felbamate: successful development of a new compound for the treatment of epilepsy.
Schmidt, D, 1993
)
3.17
"Felbamate is an investigational antiepileptic drug with a preclinical profile that suggests it would be effective in patients with multiple types of seizures."( Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).
, 1993
)
1.39
"Felbamate is a novel antiepileptic drug that is now available in the United States. "( Effect of felbamate on carbamazepine and its major metabolites.
Graves, NM; Leppik, IE; Remmel, RP; Wagner, ML, 1993
)
2.13
"Felbamate is a dicarbonate with antiepileptic effects in partial attacks and in Lennox-Gastaut syndrome."( [Felbamate: perspectives for new antiepileptic treatment].
Aguirre, J; Parrilla, JL; Pérez Miranda, M; Pérez-Miranda, J,
)
1.76
"Felbamate is a new antiepileptic drug (AED) with a good safety profile. "( Weight loss in patients taking felbamate.
Bergen, DC; Hoeppner, TJ; Kanner, A; Ristanovic, RK; Waicosky, K, 1995
)
2.02
"Felbamate is a novel anti-epileptic drug (AED) which has recently been associated with reports of aplastic anaemia and liver failure. "( Felbamate as add-on therapy.
Duncan, JS; Li, LM; Moriarty, J; Nashef, L; Sander, JW, 1996
)
3.18
"Felbamate is a new antiepileptic drug with glutamate antagonist and GABA agonist properties."( Neuroprotection with felbamate: a 7- and 28-day study in transient forebrain ischemia in gerbils.
Howlett, W; Ijaz, MS; Kanthan, R; Shuaib, A; Waqaar, T; Wishart, T, 1996
)
1.33
"Felbamate is an antiepileptic drug whose action appears to occur mainly through an interaction with neurotransmission mediated by excitatory amino acids. "( Neuroprotective effects of felbamate on global ischaemia in Mongolian gerbils.
Adami, M; Bertorelli, R; de Rino, F; Iannaccone, S; Smirne, S,
)
1.87
"Felbamate is a novel anticonvulsant which may modulate the strychnine-insensitive glycine site of the N-methyl-D-aspartate (NMDA) receptor complex. "( Effects of felbamate on veratridine- and K(+)-stimulated release of glutamate from mouse cortex.
Davies, JA; Richens, A; Srinivasan, J, 1996
)
2.13
"Felbamate is a minimally sedative, broad-spectrum anticonvulsant, whereas meprobamate is a strong sedative-anxiolytic agent."( Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate.
Donevan, SD; Rho, JM; Rogawski, MA, 1997
)
1.26
"felbamate appears to be an effective new AED: the most adverse effects occurring during administration of FBM are mild to moderate gastrointestinal (nausea, vomiting and anorexia) and central nervous system (headache, sonnolence, diplopia, dizziness and insomnia) disturbances. "( [Felbamate: a long-term study in subjects with refractory epilepsy].
De Romanis, F; Sopranzi, N, 1997
)
2.65
"Felbamate (FBM) is a new antiepileptic drug (AED) that is often effective in seizure disorders refractory to other treatments; its use has been greatly restricted after cases of aplastic anemia were reported. "( Evaluation of case reports of aplastic anemia among patients treated with felbamate.
Anderson, T; Harmon, DC; Kaufman, DW; Kelly, JP; Shapiro, S, 1997
)
1.97
"Felbamate is a broad spectrum antiepileptic drug recently introduced into clinical practice for controlling seizures in patients affected by Lennox-Gastaut epilepsy, complex partial seizures or otherwise intractable epilepsies. "( Electrophysiological effects of felbamate.
Corradetti, R; Pugliese, AM, 1998
)
2.03
"Felbamate (FBM) is a novel antiepileptic drug that was approved in 1993 for treatment of several forms of epilepsy. "( Potentially reactive cyclic carbamate metabolite of the antiepileptic drug felbamate produced by human liver tissue in vitro.
Kapetanovic, IM; Kupferberg, HJ; Macdonald, TL; McNeilly, PJ; Miller, TA; Perhach, JL; Sofia, RD; Strong, JM; Thompson, CD; Torchin, CD, 1998
)
1.97
"Felbamate is an anticonvulsant used in the treatment of seizures associated with Lennox-Gastaut syndrome and complex partial seizures that are refractory to other medications. "( Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action.
Chen, CC; Glazewski, JC; Kleckner, NW; Moscrip, TD, 1999
)
1.98
"Felbamate (FBM) is a relatively novel anticonvulsant agent which has been reported to exert its antiepileptic effects by blockade of the glycine recognition site on the N-methyl-D-aspartate subtype of glutamate receptor and potentiation at the gamma-aminobutyric acid (GABA) type A receptor. "( Neurochemical studies with the anticonvulsant felbamate in mouse brain.
Brodie, MJ; Forrest, G; Fraser, CM; Sills, GJ; Thompson, GG, 1999
)
2
"Felbamate (FBM) is a novel antiepileptic drug (AED) and neuroprotectant (NP) compound that interacts with strychnine-insensitive (SI) glycine receptors in brain (IC(50) = 374 microM). "( A self-complementary, self-assembling microsphere system: application for intravenous delivery of the antiepileptic and neuroprotectant compound felbamate.
Lian, H; McCabe, RT; Rhodes, CA; Shen, GS; Sofia, RD; Steiner, SS; White, HS; Wolf, HH; Woodhead, JH, 2000
)
1.95
"Felbamate has proven to be an effective therapy for treating refractory epilepsy. "( Role of glutathione S-transferases A1-1, M1-1, and P1-1 in the detoxification of 2-phenylpropenal, a reactive felbamate metabolite.
Dieckhaus, CM; Macdonald, TL; Roller, SG; Santos, WL; Sofia, RD, 2001
)
1.97
"Felbamate is an anti-epileptic drug associated with hepatotoxicity and aplastic anemia. "( Interaction between human serum albumin and the felbamate metabolites 4-Hydroxy-5-phenyl-[1,3]oxazinan-2-one and 2-phenylpropenal.
Dieckhaus, CM; Macdonald, TL; Roller, SG; Santos, WL; Sofia, RD, 2002
)
2.01
"Felbamate is a new dicarbamate anticonvulsant with low toxicity currently being investigated in human clinical epilepsy trials. "( Protective effects of felbamate against hypoxia in the rat hippocampal slice.
Fairchild, MD; Panizzon, KL; Wallis, RA; Wasterlain, CG, 1992
)
2.04
"Felbamate (FBM) is a novel antiepileptic drug (AED) currently undergoing clinical evaluation in the United States. "( Effect of felbamate on plasma levels of carbamazepine and its metabolites.
Albani, F; Bromfield, E; Devinsky, O; Nice, FJ; Porter, RJ; Theodore, WH; Washington, P,
)
1.98
"Felbamate is an investigational antiepileptic drug (AED) in clinical trials. "( Simultaneous assay of felbamate plus carbamazepine, phenytoin, and their metabolites by liquid chromatography with mobile phase optimization.
Graves, NM; Miller, SA; Remmel, RP, 1990
)
2.04
"Felbamate (FBM) is a novel antiepileptic drug (AED) undergoing clinical trials in the United States. "( Effect of felbamate on phenytoin and carbamazepine serum concentrations.
Fuerst, RH; Graves, NM; Holmes, GB; Leppik, IE,
)
1.98
"Felbamate is a novel antiepileptic drug currently undergoing clinical trials in the United States. "( Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trials.
Fuerst, RH; Graves, NM; Holmes, GB; Leppik, IE; Ludden, TM, 1989
)
2.04

Effects

Felbamate has demonstrated efficacy against a variety of refractory seizures types, including seizures associated with Lennox-Gastaut syndrome. Felbamate, however, has been linked with substantially increased incidence of aplastic anemia.

ExcerptReferenceRelevance
"Felbamate has been approved for refractory partial seizures since the early nineties. "( The rise and fall of felbamate as a treatment for partial epilepsy--aplastic anemia and hepatic failure to blame?
Billa, G; Chudasama, H; Goswami, S; Rane, J; Shah, R; Thakkar, K, 2015
)
2.18
"Felbamate has been associated with a high incidence of aplastic anemia and liver failure and should be used exceptionally."( Some common issues in the use of antiepileptic drugs.
Asconapé, JJ, 2002
)
1.04
"Felbamate has demonstrated efficacy against a variety of refractory seizures types, including seizures associated with Lennox-Gastaut syndrome, but postmarketing experience revealed serious idiosyncratic adverse effects that were not observed during clinical trials."( Felbamate: consensus of current clinical experience.
Faught, E; Leppik, IE; Pellock, JM; Shinnar, S; Zupanc, ML, 2006
)
2.5
"Felbamate has been used effectively as monotherapy and adjunctive therapy in patients with partial seizures with or without secondary generalization and as adjunctive therapy in children with partial or generalized seizures associated with Lennox-Gastaut syndrome."( Felbamate: a new antiepileptic drug.
Wagner, ML, 1994
)
2.45
"Felbamate has been shown previously to interact with multiple other anticonvulsant medications, including valproate, phenytoin, and carbamazepine. "( Potential pharmacokinetic interaction between felbamate and phenobarbital.
Gidal, BE; Zupanc, ML, 1994
)
1.99
"Felbamate has been proposed as a novel anticonvulsant for the treatment of generalized tonic-clonic and complex partial seizures."( Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors.
Kucharczyk, N; McCabe, RT; Sofia, RD; Vogel, JR; Wasterlain, CG, 1993
)
1.25
"Felbamate has turned out to be the first anti-epileptic with specific efficacy in Lennox-Gastaut syndrome."( [Felbamate: perspectives for new antiepileptic treatment].
Aguirre, J; Parrilla, JL; Pérez Miranda, M; Pérez-Miranda, J,
)
1.76
"Felbamate, however, has been linked with substantially increased incidence of aplastic anemia, and the other new AEDs have been studied for relatively short periods of time."( Pharmacologic and dietary therapies in epilepsy: conventional treatments and recent advances.
Chapman, DP; Giles, WH, 1997
)
1.02
"Felbamate has been shown in vitro to inhibit CYP2C19, which would account for its effect on phenytoin clearance, and it had been postulated that this could be the mechanism underlying the reduced clearance of phenobarbital by felbamate."( Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation.
Banfield, CR; Glue, P; Levy, RH; Mather, GG; Perhach, JL; Racha, JK, 1997
)
1.3
"Felbamate has proven to be an effective therapy for treating refractory epilepsy. "( Role of glutathione S-transferases A1-1, M1-1, and P1-1 in the detoxification of 2-phenylpropenal, a reactive felbamate metabolite.
Dieckhaus, CM; Macdonald, TL; Roller, SG; Santos, WL; Sofia, RD, 2001
)
1.97

Treatment

Felbamate treatment resulted in a significant 42% decrease in gestodene area under the plasma concentration-time curve. Felbamate pretreatment (300 mg/kg) reduced the surface of infarcted cortex following bilateral carotid ligation, by 42-49% compared to saline and dimethylsulfoxide (DMSO) controls.

ExcerptReferenceRelevance
"With felbamate treatment, 6 patients (16%) became seizure free, including 4 of the 6 patients with myoclonic-astatic epilepsy of Doose; 24 patients (63%) had a greater than 50% reduction in seizure frequency."( Efficacy of felbamate in the treatment of intractable pediatric epilepsy.
Chico, MS; Eggener, KA; Hecox, KE; Marcuccilli, CJ; O'Connor, SE; Roell Werner, R; Schwabe, MS; Zupanc, ML, 2010
)
1.19
"Felbamate treatment resulted in a significant 42% decrease in gestodene area under the plasma concentration-time curve (0 to 24 hours) (p = 0.018) compared with baseline, whereas a minor but not clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol."( Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive.
Banfield, CR; Colucci, RD; Glue, P; Haring, P; Lin, CC; Meehan, JW; Nomeir, A; Radwanski, E; Reidenberg, P; Saano, V, 1995
)
1.4
"The felbamate-treated patients had a 19 percent decrease in the total frequency of seizures, as compared with a 4 percent increase in the placebo group (P = 0.002)."( Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).
, 1993
)
1.15
"Felbamate pretreatment (300 mg/kg) reduced the surface of infarcted cortex following bilateral carotid ligation, by 42-49% compared to saline and dimethylsulfoxide (DMSO) controls, respectively."( Felbamate reduces hypoxic-ischemic brain damage in vivo.
Adams, LM; Hattori, H; Schwartz, PH; Wasterlain, CG, 1992
)
2.45
"Pre-treatment with felbamate was strongly protective against neuronal injury, and permitted CA1 antidromic population spike recovery to a mean 94 +/- 1% (S.E.M.) of initial amplitude, compared to unmedicated slices which regained only 15 +/- 6%."( Felbamate neuroprotection against CA1 traumatic neuronal injury.
Panizzon, KL; Wallis, RA, 1995
)
2.05
"Pretreatment with felbamate at either dose prevented the progression of rank of seizures during chronic treatment with PTZ."( Anticonvulsant effect of felbamate in the pentylenetetrazole kindling model of epilepsy in the rat.
Carboni, G; Corda, MG; Feldman, A; Frau, V; Giorgi, O; Orlandi, M; Valentini, V, 1996
)
0.92

Toxicity

ExcerptReferenceRelevance
" Finally, gabapentin is a very safe add-on medication."( The new anticonvulsant drugs. Implications for avoidance of adverse effects.
Krämer, G; Schmidt, D, 1994
)
0.29
"Standard antiepileptic drugs (AEDs) are associated with a wide variety of acute and chronic adverse events and with many interactions with each other and with non-AEDs that complicate patient management."( Overview of the safety of newer antiepileptic drugs.
Shorvon, S; Stefan, H, 1997
)
0.3
" So the search for more effective drugs with minimal adverse effect profiles will continue."( Adverse effects of new antiepileptic drugs.
Onat, F; Ozkara, C, 2004
)
0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"5%) subjects experienced adverse events including insomnia, nausea, vomiting, decreased appetite, weight loss, gastric discomfort, diarrhea, mood and behavioral problems, high blood pressure, headache, and elevated liver enzymes."( Evaluating the safety and efficacy of felbamate in the context of a black box warning: A single center experience.
Devinsky, O; Friedman, D; Kothare, SV; Shah, YD; Singh, K, 2016
)
0.71
" The mainstay of treatment is with multiple anti-seizure medications (ASMs); however, the ASMs themselves can be associated with psychobehavioural adverse events, and effects (negative or positive) on cognition and sleep."( Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.
Schubert-Bast, S; Strzelczyk, A, 2022
)
0.72

Pharmacokinetics

Felbamate (FBM) pharmacokinetic parameters, safety and tolerability in the dose range of 1,200-6,000 mg/day were assessed. No clinically relevant interactions were noted between felbamate and lamotrigine, clonazepam, vigabatrin, nor the active monohydroxy metabolite of oxcarbazepine.

ExcerptReferenceRelevance
" No sex-related differences in bioavailability and pharmacokinetic parameters were observed."( Pharmacokinetics of felbamate in pediatric and adult beagle dogs.
Adusumalli, VE; Gilchrist, JR; Kucharczyk, N; Sofia, RD; Wichmann, JK,
)
0.45
" The mean Cmax increased with dose from 13."( Felbamate pharmacokinetics in the rat, rabbit, and dog.
Adusumalli, VE; Kucharczyk, N; Sofia, RD; Wong, KK; Yang, JT,
)
1.57
" Valuable pharmacokinetic information can be obtained from the routine monitoring of serum concentrations during safety and efficacy trials."( Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trials.
Fuerst, RH; Graves, NM; Holmes, GB; Leppik, IE; Ludden, TM, 1989
)
0.6
" Pharmacokinetic parameters of phenobarbital and parahydroxyphenobarbital were determined from plasma and urine samples obtained after 28 days of daily administration of 100 mg phenobarbital and after a further 9 days of phenobarbital plus 2400 mg/day felbamate or placebo."( Effects of felbamate on the pharmacokinetics of phenobarbital.
Banfield, CR; Colucci, RD; Glue, P; Guillaume, M; Lin, CC; Meehan, JW; Mojavarian, P; Nezamis, J; Radwanski, E; Reidenberg, P, 1995
)
0.86
" Pharmacokinetic parameters of monohydroxyoxcarbazepine and dihydroxyoxcarbazepine were determined from plasma and urine samples obtained on the tenth day of each treatment period."( Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine.
Banfield, CR; Colucci, RD; Hulsman, JA; Lin, CC; Meehan, JW; Mojaverian, P; Nezamis, J; Radwanski, E; Reidenberg, P; Rentmeester, TW, 1995
)
0.68
" Pharmacokinetic assessments of ethinyl estradiol and gestodene were performed on day 14 of both cycles."( Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive.
Banfield, CR; Colucci, RD; Glue, P; Haring, P; Lin, CC; Meehan, JW; Nomeir, A; Radwanski, E; Reidenberg, P; Saano, V, 1995
)
0.68
"To report a case of a potential pharmacokinetic interaction between felbamate and phenobarbital in a patient with epilepsy."( Potential pharmacokinetic interaction between felbamate and phenobarbital.
Gidal, BE; Zupanc, ML, 1994
)
0.78
" Three of the new drugs, gabapentin, topiramate and vigabatrin, are more promising on the basis of their pharmacokinetic features."( Comparative pharmacokinetics of the newer antiepileptic drugs.
Bialer, M, 1993
)
0.29
"To assess the possible occurrence of pharmacokinetic interactions between the antiepileptic agents felbamate and vigabatrin, two randomized, double-blind, placebo-controlled, crossover studies were conducted in healthy male volunteers."( Pharmacokinetic interaction studies between felbamate and vigabatrin.
Banfield, C; Colucci, R; Glue, P; Lim, J; Lin, C; Meehan, J; Nomeir, A; Radwanski, E; Reidenberg, P; Rey, E, 1995
)
0.77
"Antiepileptic drugs (AEDs) in broad use today have a number of pharmacokinetic liabilities, including a propensity for clinically meaningful drug interactions."( Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs.
Perucca, E, 1996
)
0.29
" The 90% confidence intervals of the log-transformed pharmacokinetic parameters were within the 80-125% bioequivalance limits, however."( Effect of felbamate on the pharmacokinetics of lamotrigine.
Affrime, MB; Banfield, C; Colucci, R; Glue, P; Holt, B; Lim, J; Lin, CC; Meehan, JW; Nomeir, A; Pai, S; Reidenberg, P, 1996
)
0.7
"This article surveys the pharmacokinetic parameters for the new antiepileptic drugs (AEDs): felbamate, gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, and vigabatrin."( Pharmacokinetics of new antiepileptic drugs.
Gram, L, 1996
)
0.51
"01 l/kg per h, respectively), or in mean elimination half-life (33."( Lamotrigine pharmacokinetics in patients receiving felbamate.
Gidal, BE; Kanner, A; Lensmeyer, GL; Maly, M; Rutecki, P, 1997
)
0.55
"Compared with controls, apparent total body clearance, renal clearance and urinary excretion of felbamate were decreased, and half-life, Cmax and AUC values were increased in subjects with renal dysfunction."( Single-dose pharmacokinetics of felbamate in patients with renal dysfunction.
Affrime, MB; Banfield, C; Colucci, R; Glue, P; Lin, C; Pai, S; Sulowicz, W, 1997
)
0.8
"Single dose felbamate pharmacokinetic parameters differed between young and elderly subjects; compared with young subjects, elderly subjects had lower mean clearance (31."( Single and multiple dose pharmacokinetics of felbamate in the elderly.
Affrime, MB; Banfield, CR; Glue, P; Jensen, P; Lin, CC; Nomeir, A; Richens, A; Salfi, M, 1997
)
0.94
" No clinically relevant pharmacokinetic interactions were noted between felbamate and lamotrigine, clonazepam, vigabatrin, nor the active monohydroxy metabolite of oxcarbazepine."( Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation.
Banfield, CR; Glue, P; Levy, RH; Mather, GG; Perhach, JL; Racha, JK, 1997
)
0.81
"To conduct a population pharmacokinetic analysis of carbamazepine (CBZ)."( Population pharmacokinetics of carbamazepine in adults with epilepsy.
Ahman, P; Brundage, RC; Cascino, G; Graves, NM; Krause, S; Leppik, IE; Rarick, J; So, E; Wen, Y,
)
0.13
"Felbamate (FBM) pharmacokinetic parameters, safety and tolerability in the dose range of 1,200-6,000 mg/day were assessed in two open-label studies with similar designs."( Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy.
Lyness, WH; Narang-Sachdeo, SK; Perhach, JL; Rosenberg, A; Sachdeo, R; Shumaker, RC, 1997
)
1.99
"This open-label study investigated the pharmacokinetic interaction of phenytoin (PHT) and felbamate (FBM)."( Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate.
Lyness, WH; Perhach, JL; Rosenberg, A; Sachdeo, R; Sachdeo, S; Shumaker, RC; Wagner, ML; Ward, D, 1999
)
0.8
" PHT Cmax increased from 15."( Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate.
Lyness, WH; Perhach, JL; Rosenberg, A; Sachdeo, R; Sachdeo, S; Shumaker, RC; Wagner, ML; Ward, D, 1999
)
0.58
" For all drugs that are metabolized, half-life is shortened and clearance is increased when patients receive concomitant enzyme-inducing agents such as barbiturates, phenytoin, and carbamazepine."( The clinical pharmacokinetics of the new antiepileptic drugs.
Perucca, E, 1999
)
0.3
" In the meantime, a review of the established pharmacokinetic and pharmacodynamic activities of these agents is the first step in defining their optimal uses and limitations in the psychiatric setting."( Pharmacokinetics of new anticonvulsants in psychiatry.
Morris, HH, 1998
)
0.3
"The pharmacokinetic properties of a drug are the primary deter-minant of the extent and duration of drug action, and influence susceptibility to clinically important drug interactions."( The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?
Johannessen, SI; Perucca, E, 2003
)
0.32
" However, these combinations were associated with significant pharmacokinetic interactions, in that LCZ increased brain TPM (94%), OXC (21%), FBM (46%), and LTG (8%) concentrations."( Pharmacodynamic and pharmacokinetic interaction studies of loreclezole with felbamate, lamotrigine, topiramate, and oxcarbazepine in the mouse maximal electroshock seizure model.
Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2005
)
0.56
" However, these conclusions are confounded by the fact that LCZ is associated with significant pharmacokinetic interactions."( Pharmacodynamic and pharmacokinetic interaction studies of loreclezole with felbamate, lamotrigine, topiramate, and oxcarbazepine in the mouse maximal electroshock seizure model.
Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2005
)
0.56
" For drugs that are eliminated renally completely unchanged (gabapentin, pregabalin and vigabatrin) or mainly unchanged (levetiracetam and topiramate), the pharmacokinetic variability is less pronounced and more predictable."( Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
Johannessen, SI; Tomson, T, 2006
)
0.33
" LEV and FBM brain concentrations were measured by HPLC in order to determine any pharmacokinetic contribution to the observed antiseizure effect."( Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model.
Andres-Mach, MM; Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2007
)
0.67
"LEV in combination with FBM was associated with pharmacodynamic supraadditivity in the MES test."( Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model.
Andres-Mach, MM; Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2007
)
0.67

Compound-Compound Interactions

ExcerptReferenceRelevance
" Because of its widespread and long term use, carbamazepine is frequently prescribed in combination with other drugs, leading to the possibility of drug interactions."( Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.
Perucca, E; Pisani, F; Spina, E, 1996
)
0.29
" Felbamate administered alone or combined with lamotrigine considerably impaired exploratory and spontaneous locomotor activities of the animals tested in terms of horizontal activity."( Effect of lamotrigine combined with felbamate on the horizontal (ambulatory) activity in mice.
Andres, MM; Luszczki, JJ; Swiader, MJ, 2004
)
1.51

Bioavailability

Felbamate is well absorbed and has linear kinetics: C(max) and AUC increasing linearly with dose.

ExcerptReferenceRelevance
"The relative bioavailability and pharmacokinetics of felbamate (FBM) after a single oral dose and after 10 once-daily oral doses of 60 mg/kg were investigated in adult and pediatric dogs of both sexes."( Pharmacokinetics of felbamate in pediatric and adult beagle dogs.
Adusumalli, VE; Gilchrist, JR; Kucharczyk, N; Sofia, RD; Wichmann, JK,
)
0.7
" After oral administration, absorption is rapid and relatively efficient for the new AEDs, the most notable exception being gabapentin, whose bioavailability decreases with increasing dosage."( The clinical pharmacokinetics of the new antiepileptic drugs.
Perucca, E, 1999
)
0.3
" Felbamate is well absorbed and has linear kinetics: C(max) and AUC increasing linearly with dose."( [Therapeutic drug monitoring of felbamate].
Bentué-Ferrer, D; Tribut, O; Verdier, MC,
)
1.33
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The dosage of felbamate was titrated during the first 14 days of the treatment phase to a maximum of 45 mg per kilogram of body weight per day or 3600 mg per day. Efficacy was determined according to seizure frequency during the week prior to treatment initiation and the week after the maximal dosage was reached.

ExcerptRelevanceReference
" Animals dosed with [14C]felbamate eliminated most of the radioactivity in urine (58-87."( Felbamate pharmacokinetics in the rat, rabbit, and dog.
Adusumalli, VE; Kucharczyk, N; Sofia, RD; Wong, KK; Yang, JT,
)
1.88
"Two major and one minor metabolite of felbamate (FBM) as well as unchanged drug were isolated and identified by electron impact and chemical ionization mass spectrometry from rat and dog urine after dosing with [14C]FBM."( Felbamate metabolism in the rat, rabbit, and dog.
Adusumalli, VE; Kucharczyk, N; Sofia, RD; Wong, KK; Yang, JT,
)
1.85
" Only one subject tolerated discontinuation of CBZ; the other three had dosage reductions of 33, 54, and 63%."( Discontinuation of phenytoin and carbamazepine in patients receiving felbamate.
Graves, NM; Holmes, GB; Leppik, IE; Marienau, K; Remmel, RP; Wagner, ML,
)
0.37
" The mean felbamate dosage was 2,300 mg/d."( Felbamate for partial seizures: results of a controlled clinical trial.
Bertram, E; Cereghino, JJ; Dreifuss, FE; Drury, I; Graves, NM; Jacobs, MP; Leppik, IE; Pledger, GW; Santilli, N; Tsay, JY, 1991
)
2.13
" The daily dosage of 50 mg/kg (maximum 3,000 mg) FBM per day was well tolerated by all 28 patients who completed the study."( Felbamate: a clinical trial for complex partial seizures.
Balish, M; Bromfield, E; Devinsky, O; Ito, B; Nice, F; Porter, RJ; Raubertas, RF; Reeves, P; Theodore, WH,
)
1.57
" All patients required a PHT dosage decrease of 10-30% during active FBM treatment to maintain stable concentrations."( Effect of felbamate on phenytoin and carbamazepine serum concentrations.
Fuerst, RH; Graves, NM; Holmes, GB; Leppik, IE,
)
0.53
"Safety and efficacy studies of new antiepileptic drugs require strict adherence to prescribed dosage regimens."( Compliant populations: variability in serum concentrations.
Graves, NM; Holmes, GB; Leppik, IE, 1988
)
0.27
" Pretreatment with glycine, an agonist to the glycine/NMDA receptors, shifted the dose-response effect of felbamate to the right (ED50 = 56."( Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice.
Aguglia, U; Bertorelli, R; De Sarro, A; De Sarro, G; Ongini, E, 1994
)
0.71
" Clinical evaluation of AEDs is both difficult and complex, due mainly to two factors: (1) intermittence of clinical events, which means that dosing for periods of several weeks is generally necessary, leading to problems of poor compliance and inaccurate reporting of events by carers and patients; and (2) therapeutic necessity, which means that it is, in general, unacceptable to withhold effective treatment from a person with epilepsy."( Design of clinical antiepileptic drug trials.
Binnie, CD, 1995
)
0.29
" The highest plasma Cmax in adults dosed with 2000 mg/kg was 140."( Distribution of the anticonvulsant felbamate to cerebrospinal fluid and brain tissue of adult and neonatal rats.
Adusumalli, VE; Kucharczyk, N; Sofia, RD; Wichmann, JK,
)
0.41
"The chemistry, pharmacology, pharmacokinetics, clinical use, adverse effects, drug interactions, and dosage of felbamate are discussed."( Felbamate: a new antiepileptic drug.
Wagner, ML, 1994
)
1.94
" Consequently, the controlled trial was designed to account for this interaction by reducing the phenytoin dosage by approximately 20% during the felbamate treatment period and using matching placebo capsules to maintain the blind."( Dosage adjustments in response to monitored plasma concentrations: can unblinded staff adhere to objective criteria?
Pledger, GW; Sahlroot, JT, 1994
)
0.49
" Upon instituting felbamate, valproate dosage was reduced to 500 mg/d and phenobarbital to 200 mg/d."( Potential pharmacokinetic interaction between felbamate and phenobarbital.
Gidal, BE; Zupanc, ML, 1994
)
0.88
" Another reason why the efficacy of FBM cannot yet be fully assessed is that in all the studies the FBM dosage was limited to a maximum of 3,600 mg/day or 45 mg/kg/day."( Felbamate in the treatment of partial-onset seizures.
Bourgeois, BF, 1994
)
1.73
" ZNS daily dosage is 400-600 mg."( Antiepileptic drugs in development: prospects for the near future.
Leppik, IE, 1994
)
0.29
" Overall, approximately 50% of subjects experienced a 50% or greater reduction in total seizure frequency and a dose-response relationship was apparent."( Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial.
Dodson, WE, 1993
)
1.73
" Both studies used an identical trial design comparing FBM with a low dosage of valproate (VPA)."( Felbamate in the treatment of refractory partial-onset seizures.
Jensen, PK, 1993
)
1.73
" The effective daily dosage is approximately 30-45 mg/kg divided into three or four doses with resulting plasma concentrations of 50-80 mg/L."( Felbamate: successful development of a new compound for the treatment of epilepsy.
Schmidt, D, 1993
)
1.73
" The dosage of felbamate was titrated during the first 14 days of the treatment phase to a maximum of 45 mg per kilogram of body weight per day or 3600 mg per day, whichever was less."( Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).
, 1993
)
1.02
" We administered FBM (100 or 300 mg/kg) to 30-day-old rats 1 h after they received a convulsant dosage of kainic acid (KA)."( Neuroprotective effect of felbamate after kainic acid-induced status epilepticus.
Chronopoulos, A; Holmes, GL; Hyde, P; Mikati, M; Stafstrom, C; Thurber, S,
)
0.43
" The dose-response curves revealed IC50 of 504 nM."( Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons.
Bernardi, G; Calabresi, P; Mercuri, NB; Pisani, A; Siniscalchi, A; Stefani, A, 1996
)
1.74
" GBP is also active in this population, but only the 1,800 mg/day dosage was significantly better than placebo with respect to percent responders."( Clinical efficacy of new antiepileptic drugs in refractory partial epilepsy: experience in the United States with three novel drugs.
French, JA, 1996
)
0.29
" These findings suggest that felbamate dosing should be relatively uncomplicated in children relative to that in adults."( The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling.
Affrime, MB; Banfield, CR; Glue, P; Jen, JF; Jensen, PK; Perhach, JL; Schumaker, RC; Zhu, GR, 1996
)
0.84
" Specific indications and dosage schedules have been provided."( New antiepileptic drugs.
Brodie, MJ; Wilson, EA, 1996
)
0.29
" PTZ test was influenced by meprobamate in a fairly low dosage (ED50 66 mg/kg), but for felbamate no clearly dose-related effect could be shown up to 150 mg/kg."( Felbamate and meprobamate: a comparison of their anticonvulsant properties.
Bartels, I; Frey, HH, 1997
)
1.96
"These data suggest that initial dosage and titration of felbamate may require adjustment in patients with renal dysfunction."( Single-dose pharmacokinetics of felbamate in patients with renal dysfunction.
Affrime, MB; Banfield, C; Colucci, R; Glue, P; Lin, C; Pai, S; Sulowicz, W, 1997
)
0.83
"These findings imply that elderly subjects require lower initial dosing and slower dose titration of felbamate than non-elderly subjects."( Single and multiple dose pharmacokinetics of felbamate in the elderly.
Affrime, MB; Banfield, CR; Glue, P; Jensen, P; Lin, CC; Nomeir, A; Richens, A; Salfi, M, 1997
)
0.77
" When AUCtau, Cmax and Ctrough were adjusted for dose, there were no significant differences between the dosing periods."( Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy.
Lyness, WH; Narang-Sachdeo, SK; Perhach, JL; Rosenberg, A; Sachdeo, R; Shumaker, RC, 1997
)
0.55
"When information became available on aplastic anemia and hepatotoxicity associated with felbamate, all patients were advised to taper their felbamate dosage over approximately 2 weeks."( Increased seizure frequency associated with felbamate withdrawal in adults.
Privitera, M; Shukla, R; Welty, TE, 1998
)
0.78
"With the initiation of FBM therapy in subjects receiving PHT, the PHT dosage should be reduced by 20%."( Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate.
Lyness, WH; Perhach, JL; Rosenberg, A; Sachdeo, R; Sachdeo, S; Shumaker, RC; Wagner, ML; Ward, D, 1999
)
0.58
" The classic AEDs had numerous problems, ranging from inconvenient dosing schedules to frequent side effects due to active metabolites and common drug interactions; newer agents have been developed to avoid some of these pitfalls."( Pharmacokinetics of new anticonvulsants in psychiatry.
Morris, HH, 1998
)
0.3
" Although its half-life is relatively short (6 to 8 hours), its duration of action is longer than anticipated from its pharmacokinetics in plasma, and a twice-daily dosing regimen is adequate to produce the desired response."( The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?
Johannessen, SI; Perucca, E, 2003
)
0.32
" For these older drugs it has been common practice to adjust the dosage to achieve a serum drug concentration within a predefined 'therapeutic range', representing an interval where most patients are expected to show an optimal response."( Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
Johannessen, SI; Tomson, T, 2006
)
0.33
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
" The aim of this dose-response study was to evaluate the effect of FBM after experimental SAH in rats on (1) behavioral deficits (employing a battery of assessment tasks days 1-5 post-injury) and (2) blood-brain barrier (BBB) permeability changes (quantifying microvascular alterations according to the extravasation of protein-bound Evans Blue by a spectrophotofluorimetric technique 2 days post-injury)."( NMDA receptor antagonist felbamate reduces behavioral deficits and blood-brain barrier permeability changes after experimental subarachnoid hemorrhage in the rat.
Angileri, FF; Arcadi, F; Bramanti, P; Caffo, M; Caruso, G; Costa, C; Germanò, A; Hayes, RL; Lewis, SB; Meli, F; Newcomb-Fernandez, J; Pineda, JA; Wang, KK, 2007
)
0.64
"9%) seizure frequency was reduced by more than 50% (mean FBM dosage 3211 mg), and 13 patients (31."( [Treatment of epilepsy with third-line antiepileptic drugs: felbamate, tiagabine, and sulthiame].
Bauer, J; Chahem, J, 2007
)
0.58
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" Efficacy was determined according to seizure frequency during the week prior to treatment initiation and the week after the maximal dosage of felbamate was reached."( Efficacy and safety of felbamate in children with refractory epilepsy.
Epstein, O; Gandelman-Marton, R; Heyman, E; Lahat, E; Levin, N, 2014
)
0.91
"The aim of this review was to evaluate current literature for dosing recommendations for the use of antiepileptic medications in patients receiving renal replacement therapy (RRT)."( Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.
Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016
)
0.43
" Micromedex® DRUGDEX as well as package inserts were used to obtain known pharmacokinetic properties and dosage adjustment recommendations in RRT if known."( Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.
Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016
)
0.43
"Data regarding antiepileptic drug use in RRT are limited and mostly consist of case reports limiting our proposed dosing recommendations."( Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.
Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016
)
0.43
"Additional studies are necessary before specific dosing recommendations can be made for most antiepileptic drugs in critically ill patients receiving RRT, specifically with newer agents."( Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.
Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016
)
0.43
" The time of maximal anticonvulsant effect and the dose-response relationship of the drugs were assessed."( Effects of new antiseizure drugs on seizure activity and anxiety-like behavior in adult zebrafish.
Doboszewska, U; Guz, L; Pieróg, M; Poleszak, E; Serefko, A; Socała, K; Szopa, A; Wlaź, P; Wyska, E, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
anticonvulsantA drug used to prevent seizures or reduce their severity.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
carbamate esterAny ester of carbamic acid or its N-substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Felbamate Metabolism Pathway416
Felbamate metabolism04

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency18.29610.000811.382244.6684AID686978; AID686979
EWS/FLI fusion proteinHomo sapiens (human)Potency10.66020.001310.157742.8575AID1259253; AID1259255; AID1259256
estrogen nuclear receptor alphaHomo sapiens (human)Potency3.08960.000229.305416,493.5996AID743075
arylsulfatase AHomo sapiens (human)Potency8.49211.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency18.85410.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency0.79430.00207.533739.8107AID891
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency29.09290.00419.984825.9290AID504444
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency5.62340.01789.637444.6684AID588834
gemininHomo sapiens (human)Potency1.25820.004611.374133.4983AID624296; AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency0.03980.125912.234435.4813AID1458
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.31620.00106.000935.4813AID943
pyruvate kinase PKM isoform bHomo sapiens (human)Potency0.01002.511912.262825.1189AID954; AID958
neuropeptide S receptor isoform AHomo sapiens (human)Potency0.79430.015812.3113615.5000AID1461
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency100.00006.309660.2008112.2020AID720709
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1209455; AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (63)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
learning or memoryGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
protein heterotetramerizationGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
negative regulation of dendritic spine maintenanceGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (19)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
zinc ion bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
cytoplasmGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
lysosomeGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
late endosomeGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
cytoskeletonGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (238)

Assay IDTitleYearJournalArticle
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID684127Neurotoxicity in po dosed Sprague-Dawley albino rat assessed as minimal motor impairment by rotarod test2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates.
AID697788Antagonist activity at P2Y receptor in human HeLa cells assessed as inhibition of ATP-induced Ca2+ release at 100 uM by using fura-2AM-based fluorescence assay2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Shape-based reprofiling of FDA-approved drugs for the H₁ histamine receptor.
AID325272Inhibition of NR2B receptor Pre-M1 V558A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325254Inhibition of NR2B receptor ATD D101A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID414515Displacement of [35S]TBPS from Wistar rat brain GABAA receptor2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one) derivatives with a polar chain in position 16alpha: synthesis and activity.
AID325301Binding affinity to NR2B receptor ATD E236A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325323Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor ATD K234A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325266Inhibition of NR2B receptor Pre-M1 S548A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325281Inhibition of NR2B receptor M3c S645A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID325299Binding affinity to NR2B receptor ATD T233A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325273Inhibition of NR2B receptor Pre-M1 W559A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID325327Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor M3c S645A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID325259Inhibition of NR2B receptor ATD F182A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1312145Neurotoxicity in ip dosed albino CF1 mouse assessed as motor impairment by rotorod test2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID325263Inhibition of NR2B receptor Pre-M1 N542A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325278Inhibition of NR2B receptor M3c F642A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID684345Anticonvulsant activity in po dosed Sprague-Dawley albino rat assessed as protection against subcutaneous metrazol-induced seizures2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates.
AID1312138Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against subcutaneous metrazol-induced seizures2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID325293Inhibition of NR2B receptor post-M3 E657A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325336Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor T647A/K234A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID325333Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor L643A/K234A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID414516Displacement of [35S]TBPS from Wistar rat brain GABAA receptor relative to control2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one) derivatives with a polar chain in position 16alpha: synthesis and activity.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID325322Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor ATD T233A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325280Inhibition of NR2B receptor M3c A644C mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325288Inhibition of NR2B receptor M3c A652T mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1312137Protective index, ratio of TD50 for neurotoxicity in ip dosed albino CF1 mouse to ED50 for anticonvulsant activity in ip dosed maximal electroshock-induced seizure albino CF1 mouse model2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID325277Inhibition of NR2B receptor M3c I641A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325287Inhibition of NR2B receptor M3c A651T mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325340Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor S645A/I641A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID625293Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID684342Protective index, ratio of TD50 for po dosed Sprague-Dawley albino rat by rotarod test to ED50 for po dosed Sprague-Dawley albino rat by maximal electroshock seizures test2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID325285Inhibition of NR2B receptor M3c N649A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID113883In vivo anticonvulsant activity determined as potency that blocked clonic seizures induced by audiogenic stimuli in DBA/2 mice after pretreatment with D-serine2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Synthesis and anticonvulsant activity of novel bicyclic acidic amino acids.
AID325286Inhibition of NR2B receptor M3c L650A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325303Binding affinity to NR2B receptor M3c I643A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625294Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID325261Inhibition of NR2B receptor ATD K234A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325314Binding affinity to NR2B receptor T643A/S645A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325305Binding affinity to NR2B receptor M3c T647A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325260Inhibition of NR2B receptor ATD T233A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325271Inhibition of NR2B receptor Pre-M1 D557A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID325321Ratio of Kapp for wild type NR2B receptor to Kapp for ATD NR2B receptor F176A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID325329Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor M3c A652T mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325317Binding affinity to NR2B receptor S645A/i641A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID325258Inhibition of NR2B receptor ATD F176A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID684348Protective index, ratio of TD50 for po dosed Sprague-Dawley albino rat by rotarod test to ED50 for po dosed Sprague-Dawley albino rat by subcutaneous metrazol seizures test2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates.
AID325338Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor S645A/T103A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325296Binding affinity to NR2B receptor2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID227699Virtual screen for compounds with anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID325255Inhibition of NR2B receptor ATD T103A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325328Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor M3c T647A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID325320Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor ATD T103A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID540235Phospholipidosis-negative literature compound
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID325274Inhibition of NR2B receptor M2 N615A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID113884In vivo anticonvulsant activity determined as potency that blocked clonic seizures induced in DBA/2 mice by audiogenic stimuli2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Synthesis and anticonvulsant activity of novel bicyclic acidic amino acids.
AID325330Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor L643A/T647A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1649367Toxicity in CF1 mouse assessed as induction of motor impairment during acute (1 hr) observation period by rotarod assay
AID325334Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor L643A/S645A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325315Binding affinity to NR2B receptor S645A/T103A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID325311Binding affinity to NR2B receptor L643A/S645A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1312136Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against maximal electroshock-induced seizures2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID325283Inhibition of NR2B receptor M3c T647A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325313Binding affinity to NR2B receptor T643A/K234A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID325326Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor M3c L643A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325282Inhibition of NR2B receptor M3c Y646A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID325284Inhibition of NR2B receptor M3c A648C mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325267Inhibition of NR2B receptor Pre-M1 F550A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID325309Binding affinity to NR2B receptor L643A/T103A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325331Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor L643C/T647A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325257Inhibition of NR2B receptor ATD E106A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1312143Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against 6 Hz current-induced seizure by measuring time to peak effect2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID325291Inhibition of NR2B receptor post-M3 I655A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID325269Inhibition of NR2B receptor Pre-M1 F554A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325339Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor S645A/K234A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325325Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor M3c I641A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325253Inhibition of wild type NR2B receptor expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID325276Inhibition of NR2B receptor M3c V640A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325294Inhibition of NR2B receptor post-M3 E658A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID325332Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor L643A/T103A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325256Inhibition of NR2B receptor ATD D104A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1649358Anti-seizure activity in ip dosed CF1 mouse assessed as attenuation of psychomotor seizures at stimulus intensities of 42 mA at pre-treated at 1 hr before test by 6 Hz limbic seizure test relative to control
AID325292Inhibition of NR2B receptor post-M3 Q656A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID325297Binding affinity to NR2B receptor ATD T103A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID325308Binding affinity to NR2B receptor L643C/T647A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325307Binding affinity to NR2B receptor L643A/T647A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325262Inhibition of NR2B receptor ATD E236A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID113882In vivo anticonvulsant activity determined as potency that blocked NMDA-induced tonic seizures induced in DBA/2 mice2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Synthesis and anticonvulsant activity of novel bicyclic acidic amino acids.
AID325341Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor T103A/K234A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID325265Inhibition of NR2B receptor Pre-M1 S546A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325306Binding affinity to NR2B receptor M3c A652T mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID113885In vivo anticonvulsant activity determined as potency that blocked tonic seizures induced by audiogenic stimuli in DBA/2 mice after pretreatment with D-serine2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Synthesis and anticonvulsant activity of novel bicyclic acidic amino acids.
AID325312Binding affinity to NR2B receptor T643A/T103A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325319Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor ATD D101A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325290Inhibition of NR2B receptor post-M3 M654A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325270Inhibition of NR2B receptor Pre-M1 S555A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325304Binding affinity to NR2B receptor M3c S645A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID684339Anticonvulsant activity in po dosed Sprague-Dawley albino rat assessed as protection against maximal electroshock-induced seizures2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates.
AID325295Binding affinity to NR2B receptor ATD D101A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325337Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor T647A/S645A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID325300Binding affinity to NR2B receptor ATD K234A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID113881In vivo anticonvulsant activity determined as potency that blocked NMDA-induced clonic seizures induced in DBA/2 mice2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Synthesis and anticonvulsant activity of novel bicyclic acidic amino acids.
AID113886In vivo anticonvulsant activity determined as potency that blocked tonic seizures induced in DBA/2 mice by audiogenic stimuli2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Synthesis and anticonvulsant activity of novel bicyclic acidic amino acids.
AID325279Inhibition of NR2B receptor M3c L643A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1312140Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against maximal electroshock-induced seizures by measuring time to peak effect2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID325289Inhibition of NR2B receptor M3c F653A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325318Binding affinity to NR2B receptor T103A/K234A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID325275Inhibition of NR2B receptor M2 N616A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325264Inhibition of NR2B receptor Pre-M1 T544A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325298Binding affinity to NR2B receptor ATD F176A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325268Inhibition of NR2B receptor Pre-M1 E552A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325324Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor ATD E236A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325302Binding affinity to NR2B receptor M3c I641A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325316Binding affinity to NR2B receptor S645A/K234A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID325310Binding affinity to NR2B receptor L643A/K234A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1312141Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against subcutaneous metrazol-induced seizures by measuring time to peak effect2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID325335Ratio of Kapp for wild type NR2B receptor to Kapp for NR2B receptor T647A/T103A mutant2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (406)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (0.74)18.7374
1990's250 (61.58)18.2507
2000's87 (21.43)29.6817
2010's47 (11.58)24.3611
2020's19 (4.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 58.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index58.10 (24.57)
Research Supply Index6.21 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index92.96 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (58.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials41 (8.97%)5.53%
Reviews109 (23.85%)6.00%
Case Studies37 (8.10%)4.05%
Observational0 (0.00%)0.25%
Other270 (59.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-Blind Randomized Placebo-Controlled Trial of Felbamate in Treatment Resistant Bipolar Depression [NCT00034229]Phase 252 participants Interventional2002-04-30Completed
Population Pharmacokinetics of Antiepileptic in Pediatrics [NCT03196466]1,000 participants (Anticipated)Observational2017-06-19Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]